Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant

Experts say more real-world studies are required now

Bharat Biotech, Covaxin

Study shows that Covaxin meets the WHO efficacy criteria for Covid-19 vaccines for the dreaded Delta variant, the company said

Sohini Das Mumbai
Bharat Biotech has updated the efficacy of Covaxin to 65.2% against the Delta variant in  - Effectiveness Study on Delta Variant - Lancet Infectious Diseases, published on Nov 23 2021.

"Bharat Biotech commends the investigators from the All India Institute of Medical Sciences (AIIMS) on the BBV152 study published in Lancet Infectious Diseases. These results provide evidence for effectiveness for Covaxin in real life settings," Bharat Biotech said.

It added that an effectiveness result of 50% achieved during the peak Covid-19 Delta variant wave in India, in a high risk study population of physicians and health care workers, in a hospital environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin..

First Published: Nov 25 2021 | 08:20 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to